Back to top

Paradigm’s Phase 3 Osteoarthritis Trial Clears 80% Safety Review, Interim Analysis on Track

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals reported that an independent Data Safety Monitoring Boa...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

PAR Technology Corporation (PAR)